Day One Biopharmaceuticals to present new adenoid cystic carcinoma data at ASCO26 on June 1

Day One Biopharmaceuticals to present new adenoid cystic carcinoma data at ASCO26 on June 1
Day One unveils ACC study data

Day One Biopharmaceuticals will present new clinical data for its investigational medicine targeting adenoid cystic carcinoma (ACC) during an oral presentation at ASCO26 on June 1.

The company aims to engage with the oncology research and care community at the annual conference, highlighting progress in treatments for rare cancers. Further information about the presentation is available through the company’s official channels.

Day One Biopharmaceuticals has expanded its clinical pipeline with additional rare cancer indications this year. The company previously completed enrollment for its FIREFLY-2 trial, which is focused on front-line treatment of pediatric low-grade glioma. Analysts are watching the company’s efforts as it progresses multiple investigational programs in oncology.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.